Literature DB >> 2404572

Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.

N J Crowley1, C L Slingluff, T L Darrow, H F Seigler.   

Abstract

Autologous tumor-specific cytotoxic T-lymphocytes (CTLs), generated by repeated stimulation with autologous melanoma and expanded in interleukin 2, are major histocompatibility complex restricted. These CTLs recognize a common tumor-associated antigen in the presence of HLA class I determinants, suggesting that allogeneic melanomas which express the restricting HLA-A region antigen could substitute for the autologous tumor in the generation of CTLs. This was investigated in the HLA-A2 system. Four T-cell lines were established by stimulation of lymphocytes with either autologous tumor or an HLA-A2-matched allogeneic melanoma. Allogeneic stimulated CTLs specifically lysed the autologous tumor and demonstrated an identical pattern of HLA-A2 restriction, when compared to the autologous stimulated CTLs. Lysis by the allogeneic stimulated CTLs was blocked by a monoclonal antibody to HLA class I antigens; lysis was also inhibited by both autologous tumor or HLA-A2 allogeneic melanomas when evaluated in cold target competition studies. The allogeneic stimulated CTLs proliferated in response to both autologous tumor and HLA-A2 melanomas, but not in response to HLA-A2 nonmelanomas. By phenotypic analysis these CTLs were CD3+ and predominantly CD8+ cells. We conclude that autologous tumor-specific CTLs can be generated using HLA-A region-matched allogeneic melanomas for stimulation. Since established, HLA-typed melanoma tumor lines can be used in the absence of autologous tumor; this procedure can be applied clinically to a broad patient population and may prove useful in the adoptive immunotherapy of melanoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells.

Authors:  C J Bartels; S A Rosenberg; J C Yang
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

3.  Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells.

Authors:  W Sherman; Z Liu; G Inghirami; E F Reed; P E Harris; N M Suciu-Foca
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

5.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

6.  Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.

Authors:  D L Shawler; R M Bartholomew; M A Garrett; R J Trauger; O Dorigo; C Van Beveren; A Marchese; F Ferre; C Duffy; D J Carlo; L A Sherman; D P Gold; R E Sobol
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Authors:  Y Hayashi; D S Hoon; M S Park; P I Terasaki; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.

Authors:  F Arienti; F Belli; L Rivoltini; C Gambacorti-Passerini; L Furlan; L Mascheroni; A Prada; M Rizzi; E Marchesi; M Vaglini
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

9.  Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2.

Authors:  M B Leger-Ravet; C Mathiot; A Portier; M Brandely; P Galanaud; W H Fridman; D Emilie
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

10.  Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.

Authors:  M Laude; K L Russo; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.